Metastatic pancreatic adenocarcinoma: Current standards, future directions

Austin Duffy, Shivaani Kummar

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Pancreatic cancer is the fourth most common cause of cancer death in the United States. In the landmark study in 1997, which established the central although modest role of gemcitabine in this disease, progress has been incremental. Significant developments have been an increased acceptance for combination chemotherapy in patients with good performance status in addition to an increased understanding of tumorigenesis. The parallel technologic and engineering developments that have occurred hold the promise of exploiting this understanding. This review attempts to summarize the standard therapeutic approach to metastatic pancreatic cancer and point to areas that hold promise for the future.

Original languageEnglish (US)
Pages (from-to)79-85
Number of pages7
JournalAmerican Journal of Therapeutics
Issue number1
StatePublished - Jan 2010
Externally publishedYes


  • Metastatic
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Metastatic pancreatic adenocarcinoma: Current standards, future directions'. Together they form a unique fingerprint.

Cite this